Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
暂无分享,去创建一个
A. Gastaldelli | E. Bugianesi | G. Saracco | D. Ribaldone | M. Gaggini | F. Carli | G. P. Caviglia | C. Rosso | M. Abate | A. Olivero | A. Armandi
[1] SeP is elevated in NAFLD and participates in NAFLD pathogenesis through AMPK/ACC pathway , 2020, Journal of cellular physiology.
[2] A. Gastaldelli,et al. Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease , 2019, International journal of molecular sciences.
[3] A. Gastaldelli,et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease. , 2019, Journal of hepatology.
[4] H. Misu. Identification of hepatokines involved in pathology of type 2 diabetes and obesity. , 2019, Endocrine journal.
[5] L. Duntas,et al. Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease. , 2019, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[6] U. Nöthlings,et al. Metabolomics signature associated with circulating serum selenoprotein P levels , 2018, Endocrine.
[7] A. Gastaldelli,et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance , 2018, Hepatology.
[8] L. Henry,et al. NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .
[9] L. Heilbronn,et al. Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance. , 2017, Obesity research & clinical practice.
[10] A. Gentilini,et al. Molecular Pathogenesis of NASH , 2016, International journal of molecular sciences.
[11] E. Bugianesi,et al. Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. , 2016, Clinics in liver disease.
[12] E. Bugianesi,et al. Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load , 2016, International journal of molecular sciences.
[13] H. Steinbrenner. Interference of selenium and selenoproteins with the insulin-regulated carbohydrate and lipid metabolism. , 2013, Free radical biology & medicine.
[14] H. J. Yoo,et al. Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease , 2013, Diabetes & metabolism journal.
[15] M. Capecchi,et al. Production of Selenoprotein P (Sepp1) by Hepatocytes Is Central to Selenium Homeostasis* , 2012, The Journal of Biological Chemistry.
[16] E. Brunt,et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. , 2012, Journal of hepatology.
[17] J. Hardies,et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease , 2012, Hepatology.
[18] C. Palmeira,et al. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. , 2012, Free radical biology & medicine.
[19] H. J. Yoo,et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. , 2011, The Journal of clinical endocrinology and metabolism.
[20] M. Honda,et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. , 2010, Cell metabolism.
[21] G. Marchesini,et al. Insulin resistance in nonalcoholic fatty liver disease. , 2010, Current pharmaceutical design.
[22] R. Burk,et al. Selenoprotein P-expression, functions, and roles in mammals. , 2009, Biochimica et biophysica acta.
[23] Svati H Shah,et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.
[24] E. Ferrannini,et al. Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes , 2007, Clinical pharmacology and therapeutics.
[25] J. Park. [Insulin resistance in non-alcoholic fatty liver disease]. , 2006, The Korean journal of hepatology.
[26] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[27] E. Çakır,et al. Systemic Markers of Lipid Peroxidation and Antioxidants in Patients with Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.
[28] E. Ferrannini,et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.
[29] Morihiro Matsuda,et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.
[30] A. Laudanna,et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline‐deficient diet , 2002, Journal of cellular and molecular medicine.
[31] J. Köhrle,et al. Transforming growth factor‐β1 inhibits expression of selenoprotein P in cultured human liver cells , 1999 .
[32] J. Abel,et al. Transforming growth factor-beta1 inhibits expression of selenoprotein P in cultured human liver cells. , 1999, FEBS letters.
[33] C. Day,et al. Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.